Clinical Trials

Phase 3 Active not recruiting

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

296 enrolled 28 charts 1 FDA

303 enrolled 31 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

44 enrolled 22 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Phase 1 Terminated

CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

NCT03672643 2024-11-08

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Phase 4 Terminated

41 enrolled 9 charts

364 enrolled 89 charts 1 FDA

ALK or ROS1-positive NSCLC

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02679170 2024-08-09

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

692 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT02584634 2023-07-07

Javelin Lung 101

Phase 1/2 Terminated

43 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

275 enrolled 23 charts 2 FDA

ALK-positive NSCLC

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT02574078 2021-05-06

CheckMate370

Phase 1/2 Completed

341 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT01945021 2021-02-21

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Phase 2 Completed

129 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01639001 2020-12-08

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Phase 3 Completed

207 enrolled 29 charts

Carcinoma, Non-Small-Cell Lung

NCT01999972 2020-09-24

A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors

50 enrolled 29 charts

Tumor-Agnostic

Carcinoma

NCT01597258 2019-09-13

Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)

2,029 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT02511184 2019-07-01

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Phase 1 Terminated

9 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01576406 2018-10-25

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

88 enrolled 44 charts

Advanced Cancer

NCT00932451 2017-01-13

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Phase 2 Completed

1,069 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT00965731 2015-10-28

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

27 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01121575 2015-10-28

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

70 enrolled 50 charts